Two doses of adjuvanted recombinant zoster vaccine following autologous hematopoietic stem cell transplant led to rapid and durable cell-mediated immune responses, results from a subgroup analysis of a large randomized, placebo-controlled trial showed.1
Premal Lulla, MD, discusses the need for cellular therapies for patients with leukemia after transplant.
Sergio A. Giralt, MD, discusses the role of allogeneic hematopoietic cell therapy in patients with multiple myeloma.
Christopher E. Dandoy, MD, MSc, says that patients undergoing allogenic stem cell transplant are at high-risk of developing thrombotic microangiopathy.
Christopher E. Dandoy, MD, MSc, discussed how higher levels of soluble suppression of tumorigenicity-2 and soluble terminal complement complex were associated with high-risk thrombotic microangiopathy, a severe complication related to stem cell transplantation.
Transplant-associated thrombotic microangiopathy occurred in as many as 36% of hematopoietic cell transplants and significantly increased the risk of transplant-related mortality.
Richard E. Champlin, MD, a professor of medicine at MD Anderson Cancer Center, discusses the association seen between the Endothelial Activation and Stress Index (EASIX) and fluid overload and survival in patients who underwent an allogenic stem cell transplantation.
Shaji Kumar, MD, of Mayo Clinic, advises physicians on the use of autologous stem cell transplant in patients with newly diagnosed multiple myeloma.
Frederick L. Locke, MD, discusses the optimal management of chimeric antigen receptor T-cell therapy-related adverse events.
Patients with relapsed/refractory chronic lymphocytic leukemia had an improved response rate with chimeric antigen receptor T-cell therapy if they also received ibrutinib.
Adults with acute lymphoblastic leukemia had worse outcomes, including lower survival, after myeloablative allogeneic transplantation if they remained positive for minimal residual disease at the time of transplant.
Gareth Morgan, MD, discusses the TOURMALINE-MM3 findings in multiple myeloma and other clinical trials that are impacting the landscape for this patient population.
Arlene O. Siefker-Radtke, MD, discusses the promising preliminary data with bempegaldesleukin plus nivolumab in patients with metastatic urothelial carcinoma and the next steps for this combination.
Single-agent pembrolizumab (Keytruda) showed encouraging antitumor activity as first-line treatment in patients with non-clear cell renal cell carcinoma, especially in those with papillary or unclassified histology.
Evan Y. Yu, MD, highlights 2 key studies with PARP inhibitors in metastatic castration-resistant prostate cancer and discussed challenges that need to be addressed in this space in order to further progress.
Arlene O. Siefker-Radtke, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the promise of bempegaldesleukin plus nivolumab in the treatment of patients with metastatic urothelial carcinoma.
Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses durvalumab in combination with a MET inhibitor in the treatment of patients with papillary renal cancer.
The overall response rate achieved with with the combination of savolitinib and durvalumabin in patients with metastatic papillary renal cell carcinoma in the phase II CALYPSO study did not meet the prespecified criterion for further investigation of the regimen.
The combination of pembrolizumab (Keytruda) and cabozantinib (Cabometyx) has antitumor activity in patients with previously treated metastatic renal cell carcinoma and is tolerated at their separate approved doses for this indication.
Sacituzumab govitecan exhibited significant clinical activity in an open-label, single-arm phase I/II basket study of patients with heavily pretreated, relapsed/refractory metastatic urothelial cancer.
Arpita Desai, MD, medical oncologist, University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the rationale for testing MRI functional imaging for bone metastases in men with castration-resistant prostate cancer.
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses avelumab/axitinib data in renal cell carcinoma.
In a real-world setting, patients with metastatic castration-resistant prostate cancer who received radium-223 dichloride with abiraterone acetate in a layered fashion experienced a lower rate of symptomatic skeletal events compared with those who received the treatments concurrently.
The addition of enzalutamide (Xtandi) to androgen deprivation therapy significantly prolonged radiographic progression-free survival compared with ADT alone in men with metastatic hormone-sensitive prostate cancer.
Darolutamide added to androgen deprivation therapy significantly improved metastasis-free survival compared with placebo plus ADT in patients with nonmetastatic castration-resistant prostate cancer enrolled in the phase III ARAMIS trial.
Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the rationale for the KEYNOTE-057 study in patients with non–muscle invasive bladder cancer.
Scott T. Tagawa, MD, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine & urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian–Weill Cornell Medical Center, discusses sacituzumab govitecan in the treatment of patients with urothelial carcinoma.
Nivolumab combined with low-dose ipilimumab continued to demonstrate strong responses and a survival benefit at 30 months’ follow-up as a frontline treatment for patients with intermediate- and poor-risk advanced renal cell carcinoma.
The combination of pembrolizumab (Keytruda) and axitinib (Inlyta) was associated with a significantly longer progression-free and overall survival compared with sunitinib (Sutent) in treatment-naïve patients with clear cell metastatic renal cell carcinoma.
African-American men with metastatic castration-resistant prostate cancer treated with novel hormonal therapies—namely abiraterone acetate or enzalutamide—lived 20% longer than their Caucasian counterparts.
